The PCCTC is a premier multicenter clinical research organization specializing in cutting-edge prostate cancer research recognized for its culture of transparent project co-development between investigators, research sites and industry partners. The group’s distinguished investigators work together on a single mission: to design, implement and complete hypothesis-driven trials in prostate cancer, translating scientific discoveries into improved standards of care.
Lantheus’ prostate cancer AI platform, which includes FDA cleared medical devices for both PSMA PET/CT (aPROMISE) and bone scintigraphy (aBSI), will be used in specific clinical studies to assist in measuring imaging response in patients diagnosed with prostate cancer.
The intent of the strategic collaboration is to integrate Lantheus’ AI platform into early phase PCCTC studies to advance the discovery, development and validation of novel AI-enabled biomarkers. Imaging biomarkers have the potential to play a significant role in both patient selection and response assessment of targeted therapies. Lantheus’ AI platform has the potential to reduce the complexity and improve the utility of the rich data generated from the diverse imaging tools used in prostate cancer, including PSMA PET/CT, bone scintigraphy, MRI and CT.
“The PCCTC’s mission is to make a significant impact on the lives of patients by keeping the pipeline primed with the most promising novel agents and validated biomarkers,” said
“Lantheus believes its artificial intelligence platform can expand the utility of imaging diagnostics for precision medicine in prostate cancer and evolve from single biomarker image analysis to an integrated clinical decision support system drawing on multiple biomarkers and clinical record data. This strategic partnership is a critical step forward to realize that vision,” said
Prostate Cancer AI Platform
Lantheus’ prostate cancer artificial intelligence platform includes FDA and CE cleared medical devices for both PSMA PET/CT and bone scintigraphy.
The aPROMISE product is a vendor-neutral stand-alone software as a medical device which quantifies PSMA PET/CT in prostate cancer. aPROMISE received FDA clearance in 2021 (K 211655). The product is enabled with a unique deep learning algorithm that leverages a novel database to assist in automated localization, segmentation, and quantification of potential lesions – a PSMA score/PSMA Scan Index.
The aBSI product is a vendor-neutral stand-alone software as a medical device that calculates the automated bone scan index in Technetium-99m bone scintigraphy of prostate cancer patients. aBSI received FDA clearance in 2019 (K191262). The product is enabled with a neural network that has been trained to automate the detection of hotspots and calculate the aBSI value.
About Prostate Cancer
Prostate cancer is the second most common form of cancer affecting men in
About
About
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “advance,” “development,” “evolve,” “expand,” “objective,” “potential,” “vision,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) the PCCTC’s ability to successfully integrate the Company’s AI platform into early phase PCCTC studies; (ii) the intellectual property protection of the Company’s AI platform; (iii) interruptions or performance problems associated with our AI platform, including a service outage; (iv) a network or data security incident that allows unauthorized access to our network or data or the PCCTC’s investigators’ data; and (v) the risks and uncertainties discussed in our filings with the
1
Contacts:
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com
Director, Corporate Communications
646-975-2533
media@lantheus.com
Source:
2022 GlobeNewswire, Inc., source